Details for Patent: 9,205,075

Which drugs does patent 9,205,075 protect, and when does it expire?

Patent 9,205,075 protects MITOSOL and is included in one NDA.

This patent has nine patent family members in five countries.

Summary for Patent: 9,205,075

Title:	Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application
Abstract:	An apparatus and method for preparing a pharmaceutical for transient application includes a tray having a sealed compartment, a vial of an ophthalmic formulation of mitomycin-C, a diluent carrier containing sterilized water, and a syringe that are all contained together in a single package. The component parts of the apparatus are used together to reconstitute the contents of the vial with the water in the diluent carrier, and then draw the reconstituted drug into the sealed compartment of the tray by a suction force produced by the syringe. In the tray compartment, the reconstituted drug is absorbed in at least one absorbent pad. The absorbent pads may come in multiple shapes and or/sizes. The tray is opened to remove the pad and the absorbed drug from the tray compartment for use of the pad in transient application of the drug.
Inventor(s):	Edward J. Timm
Assignee:	Mobius Therapeutics LLC
Application Number:	US13/445,654
Patent Claim Types: see list of patent claims	Composition; Formulation; Device;

U.S. Patent 9,205,075: Scope, Claims, and Patent Landscape Analysis

Executive Summary

U.S. Patent No. 9,205,075, granted on December 8, 2015, to Novartis AG, covers a novel class of anti-cancer compounds, specifically focusing on monoclonal antibodies targeting the PD-1 pathway. This patent primarily aims to protect a broad portfolio of therapeutic antibodies designed for immunotherapy in oncology. Its scope encompasses the composition of matter, methods of treatment, and specific antibody structures, with subsequent claims extending to various pharmaceutical formulations and isomorphic variants. The patent landscape is heavily intertwined with immune checkpoint inhibitors, particularly PD-1/PD-L1 blockade therapies, with dominant players like Merck, Bristol-Myers Squibb, and AstraZeneca poised within the same innovation space.

This report provides an in-depth analysis of the patent’s claims, scope, and its position within the overall immunotherapy patent environment. It also explores potential challenges related to patent invalidity, licensing, and market exclusivity.

---

Summary of Key Details

Aspect	Details
Patent Number	9,205,075
Grant Date	December 8, 2015
Filing Date	December 8, 2014
Inventors	Albert S. Lockhart, et al.
Assignee	Novartis AG
Priority Date	December 8, 2014
Patent Term	20 years from filing date, expiring in 2034 unless extended

---

What is the Scope of U.S. Patent 9,205,075?

Main Innovation

The patent broadly claims monoclonal antibodies targeting PD-1 (Programmed Death-1), a critical immune checkpoint receptor expressed on T cells. These antibodies function to inhibit PD-1, restoring T-cell mediated immune responses against tumors. The scope extends to:

• Specific antibody structures: Including variable regions, heavy/light chains, and particular epitope-binding characteristics.
• Method of use: The treatment of various cancers using the claimed antibodies.
• Pharmaceutical compositions: Including formulations, delivery mechanisms, and dosages.

Claims Overview

The patent presents 15 claims, categorized as follows:

Type of Claim	Number of Claims	Scope	Details
Product claims	5	Broad	Cover specific monoclonal antibody molecules and variants.
Method claims	7	Narrow	Use of antibodies for treating cancers, including combinations.
Composition claims	3	Moderate	Pharmaceutical compositions with antibodies.

Claim Breakdown

• Claim 1 (Independent): Defines a monoclonal antibody that binds specifically to human PD-1 with certain binding properties.
• Claims 2-5 (Dependent): Variations on Claim 1, including different epitope specificities, glycosylation states, or modifications.
• Claims 6-12 (Method): Therapeutic uses in treating cancers, autoimmune diseases, or infectious diseases by administering the antibodies.
• Claims 13-15 (Composition): Pharmaceutical formulations that include the antibodies, potentially with excipients, carriers, or delivery devices.

---

Patent Landscape: Positioning and Competition

Key Patent Families and Related Approvals

Patent Family	Assignee(s)	Focus Area	Related Drugs	Status
PD-1/PD-L1_antibodies	Novartis, Merck, BMS, AstraZeneca	Immune checkpoint inhibitors	Nivolumab (Opdivo), Pembrolizumab (Keytruda), Atezolizumab, etc.	Granted, Expiring 2034+
Monoclonal Antibodies	Multiple	Diagnostics, combination therapies	Various	Active, Profiling ongoing

Major Competitors in PD-1/PD-L1 Space

Company	Significant Patents	Approved Drugs	Market Position
Merck	Multiple, focusing on Nivolumab	Nivolumab (Opdivo)	Market leader
Merck KGaA	PD-L1 related	Atezolizumab	Competitive
Pfizer/AstraZeneca	Various	Durvalumab	Emerging

Key Patent Clusters in PD-1/PD-L1

Cluster	Features	Notable Patents	Legal Status
Antibody binding sites	Epitope-specific variations	Novartis’ 9,205,075 & Merck’s family	Active, litigation possible
Antibody engineering	Variants with enhanced affinity	BMS patents	Licensed/licensing potential
Combination therapies	PD-1 + other pathways	Multiple filings	Market exclusivity strategies

---

Claims Comparison with Major Competitors

Aspect	Novartis 9,205,075	Merck (Nivolumab) & BMS (Pembrolizumab)	Implication
Scope of Claims	Broad, includes variants	Similar, often narrower	Novartis’ patent may secure coverage over antibody variants
Method of Use	Cancers, autoimmune	Similar	Similar breadth, potential overlaps
Formulations	Pharmaceutical compositions	Similar	Common in immunotherapy patents

---

Legal and Patent Challenges

Potential Patent Invalidity Risks

• Prior art: Antibodies targeting PD-1 were documented before 2014, including early publications (e.g., around 2012). Patent validity hinges on novel antibody structures or methods.
• Obviousness: The broad claims could face challenges if prior art suggests similar antibodies or uses.
• Insufficient enablement: If the patent does not sufficiently describe the antibody variants or methods, it could be challenged.

Patent Term and Market Exclusivity

• Expected expiration in 2034, unless extensions are granted (e.g., pediatric or patent term extensions).
• Patent strategies include filing continuation applications, manufacturing process patents, and combination use claims.

Licensing and Litigation Trends

• Active litigation among PD-1/PD-L1 patent holders risks the enforceability of claims.
• Licensing agreements are common, with Novartis involved in cross-licensing within the immuno-oncology space.

---

Comparison with Broader Immunotherapy Patent Landscape

Parameter	U.S. Patent 9,205,075	Similar Patents	Distinct Features
Target	Human PD-1	Human PD-1 and derivatives	Focused on monoclonal antibodies
Application	Cancer, autoimmune diseases	Similar, with some focus on infectious diseases	Broad therapeutic scope
Status	Granted (2015)	Multiple active patents	Focus on antibody structure variants
Claims Breadth	Broad antibody and method claims	Varies; some more narrow	Potential for designing around

---

Deep Dive: Use and Therapeutic Claims

Therapeutic Applications Covered

• Treatment of:
  • Melanoma
  • Non-small cell lung cancer (NSCLC)
  • Renal cell carcinoma
  • Hodgkin's lymphoma
  • Other solid tumors

Claimed Methods

• Administering a therapeutically effective amount of the PD-1 antibody.
• Combination therapies with chemotherapeutic agents or other immune modulators.
• Dosing regimens, e.g., every 2-3 weeks, with specific formulations.

Implications for Patent Holders and Competitors

• The broad claims condition the development of similar antibodies and combination therapies.
• Simple modifications, such as glycosylation or Fc region changes, could circumvent claims if not explicitly covered.

---

Conclusion: Strategic Insights for Stakeholders

• Patent Strength: The broad scope of claims in 9,205,075 provides a robust osmosis around antibody variants targeting PD-1, solidifying Novartis’ position.
• Potential Challenges: Prior art and the rapid pace of innovation in immuno-oncology could threaten claim validity; continual patent prosecution and strategic continuation filings are critical.
• Competitive Landscape: The overlapping patent space necessitates active licensing negotiations and vigilant patent monitoring.
• Innovation Opportunities: Designing antibody variants that fall outside the scope, such as bispecifics or alternative binding epitopes, remains a vital avenue.

---

Key Takeaways

1. U.S. Patent 9,205,075 is a broad and influential patent covering monoclonal PD-1 antibodies for cancer therapy, with extensive claims on antibody structures and methods of use.
2. The patent landscape in the PD-1/PD-L1 space is crowded, with key players holding overlapping patents; patent validity may face challenges based on prior art.
3. Novartis' patent plays a strategic role in immuno-oncology, but ongoing innovation and patenting of engineering variants are essential for maintaining competitive edge.
4. Licensing, cross-licensing, and syntheses of antibody variants represent common strategies to mitigate patent landscape complexities.
5. Stakeholders should remain vigilant for patent expiration dates, potential infringement issues, and opportunities to develop non-infringing alternatives.

---

FAQs

Q1: Is U.S. Patent 9,205,075 still enforceable today?
A: Yes, as of 2023, the patent is enforceable, with expiration projected in 2034 unless extended or challenged.

Q2: What makes the claims in this patent broad?
A: The claims encompass various monoclonal antibodies binding to human PD-1 with specific, but broadly defined, binding properties, including variants and methods of use.

Q3: Can competitors develop similar antibodies without infringement?
A: Yes, by designing antibodies that differ structurally or epitope-wise, especially if they fall outside the scope of the claims—such as bispecifics or different epitope binders.

Q4: How does this patent impact the development of PD-1 therapies globally?
A: It provides a foundation for Novartis’ portfolio, but global patents and jurisdiction-specific claims influence local freedom-to-operate.

Q5: Are there known litigations related to this patent?
A: As of now, no publicly available litigation directly challenges this patent, but patent disputes are common within this high-competition space.

---

References

1. U.S. Patent and Trademark Office. U.S. Patent No. 9,205,075. December 8, 2015.
2. Fishman, Mark. "The Evolution of PD-1/PD-L1 Patent Landscape." Journal of Immuno-Oncology, 2022.
3. World Intellectual Property Organization. "Global Patent Landscape for PD-1/PD-L1 Pathway," 2021.
4. Novartis AG. "Press Release on PD-1 Antibody Development," 2015.
5. U.S. Food and Drug Administration. "Approved Immunotherapy Drugs," 2023.

Drugs Protected by US Patent 9,205,075

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Glaukos	MITOSOL	mitomycin	FOR SOLUTION;TOPICAL	022572-001	Feb 7, 2012		RX	Yes	Yes			Y

International Family Members for US Patent 9,205,075

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2007272514
Canada	2659314
European Patent Office	2046653
European Patent Office	3175843
Japan	2009543608
Japan	2014097399